Rituxan (rituximab) - Roche
RiTOX: Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events (clinicaltrials.gov) - Oct 21, 2026 - P1 | N=25 | Recruiting | Sponsor: Inge Marie Svane | Not yet recruiting ➔ Recruiting 
Enrollment open • Oncology
http://clinicaltrials.gov/ct2/show/NCT07694414
 
Oct 21, 2026
 
Prev Next